SidaSubSaharaV1, Istex, Corpus, bibRecord, 004E57

Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load

Identifieur interne : 004E57 ( Istex/Corpus ); précédent : 004E56; suivant : 004E58

Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load

Auteurs : Vincent Soriano ; Perpétua Gomes ; Walid Heneine ; Africa Holguín ; Manuela Doruana ; Rute Antunes ; Kamal Mansinho ; William M. Switzer ; Carlos Araujo ; Vedapuri Shanmugam ; Helena Lourenço ; Juan González-Lahoz ; Francisco Antunes

Source :

Journal of Medical Virology [ 0146-6615 ] ; 2000-05.

RBID : ISTEX:F14A622501FF9A53D5567AD920B384E3635A1D01

English descriptors

Abstract

The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as more pathogenic than the rest. The relationship between the clinical status and levels of both cellular and plasma HIV‐2 viraemia is not well known, nor their modifications under antiretroviral therapy. Thirty‐two consecutive HIV‐2 infected persons (17 men, 15 women) attending two different hospitals in Lisbon in 1997 were enrolled prospectively in the study. All but 4 individuals most likely acquired the infection through heterosexual contact. More than half of the study population was of African origin, mainly from Guinea‐Bissau. Eleven (34.4%) patients had developed clinical manifestations included within the B or C groups of the CDC classification system for HIV infection, with the rest being asymptomatic. Half of the population was undergoing antiretroviral treatment at the time of the study. HIV‐2 subtypes were investigated using a new Nef‐based restriction fragment length polymorphism (RFLP) method that allows differentiation of the main two variants, A and B. Plasma viral load was quantified using a new quantitative competitive reverse transcriptase polymerase chain reaction (QcRT‐PCR) procedure as well as the Amp‐RT assay. Virus isolation was attempted from peripheral blood mononuclear cells. All but one person carried HIV‐2 subtype A. Plasma viraemia examined by QcRT‐PCR was measurable in 15 (50%) of 30 subjects, yielding in all instances values below 20,000 HIV‐2 RNA copies per ml. Plasma RT activity could be detected in only 10 (33%) of 30 subjects, a rate much lower than that seen in HIV‐1 infection. Virus was isolated from 16 (53.3%) of 30 patients. A significant correlation was found between CD4+ counts, clinical status, rate of virus isolation, and plasma viral load by both QcRT‐PCR and Amp‐RT. In conclusion, HIV‐2 subtype A is the predominant variant circulating in Portugal among both natives and immigrants. A lower cellular and plasma viral load with respect to HIV‐1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low. J. Med. Virol. 61:111–116, 2000. © 2000 Wiley‐Liss, Inc.

Url:

https://api.istex.fr/document/F14A622501FF9A53D5567AD920B384E3635A1D01/fulltext/pdf

DOI: 10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W

Links to Exploration step

ISTEX:F14A622501FF9A53D5567AD920B384E3635A1D01

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
<author><name sortKey="Soriano, Vincent" sort="Soriano, Vincent" uniqKey="Soriano V" first="Vincent" last="Soriano">Vincent Soriano</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: vsoriano@dragonet.es</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence address: C/Rafael Calvo 7, 2° A, 28010 Madrid, Spain===</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Gomes, Perpetua" sort="Gomes, Perpetua" uniqKey="Gomes P" first="Perpétua" last="Gomes">Perpétua Gomes</name>
<affiliation><mods:affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Heneine, Walid" sort="Heneine, Walid" uniqKey="Heneine W" first="Walid" last="Heneine">Walid Heneine</name>
<affiliation><mods:affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Holguin, Africa" sort="Holguin, Africa" uniqKey="Holguin A" first="Africa" last="Holguín">Africa Holguín</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Doruana, Manuela" sort="Doruana, Manuela" uniqKey="Doruana M" first="Manuela" last="Doruana">Manuela Doruana</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Antunes, Rute" sort="Antunes, Rute" uniqKey="Antunes R" first="Rute" last="Antunes">Rute Antunes</name>
<affiliation><mods:affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mansinho, Kamal" sort="Mansinho, Kamal" uniqKey="Mansinho K" first="Kamal" last="Mansinho">Kamal Mansinho</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Switzer, William M" sort="Switzer, William M" uniqKey="Switzer W" first="William M." last="Switzer">William M. Switzer</name>
<affiliation><mods:affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Araujo, Carlos" sort="Araujo, Carlos" uniqKey="Araujo C" first="Carlos" last="Araujo">Carlos Araujo</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Shanmugam, Vedapuri" sort="Shanmugam, Vedapuri" uniqKey="Shanmugam V" first="Vedapuri" last="Shanmugam">Vedapuri Shanmugam</name>
<affiliation><mods:affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lourenco, Helena" sort="Lourenco, Helena" uniqKey="Lourenco H" first="Helena" last="Lourenço">Helena Lourenço</name>
<affiliation><mods:affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Gonzalez Ahoz, Juan" sort="Gonzalez Ahoz, Juan" uniqKey="Gonzalez Ahoz J" first="Juan" last="González-Lahoz">Juan González-Lahoz</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Antunes, Francisco" sort="Antunes, Francisco" uniqKey="Antunes F" first="Francisco" last="Antunes">Francisco Antunes</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F14A622501FF9A53D5567AD920B384E3635A1D01</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W</idno>
<idno type="url">https://api.istex.fr/document/F14A622501FF9A53D5567AD920B384E3635A1D01/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004E57</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004E57</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
<author><name sortKey="Soriano, Vincent" sort="Soriano, Vincent" uniqKey="Soriano V" first="Vincent" last="Soriano">Vincent Soriano</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: vsoriano@dragonet.es</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Correspondence address: C/Rafael Calvo 7, 2° A, 28010 Madrid, Spain===</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Gomes, Perpetua" sort="Gomes, Perpetua" uniqKey="Gomes P" first="Perpétua" last="Gomes">Perpétua Gomes</name>
<affiliation><mods:affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Heneine, Walid" sort="Heneine, Walid" uniqKey="Heneine W" first="Walid" last="Heneine">Walid Heneine</name>
<affiliation><mods:affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Holguin, Africa" sort="Holguin, Africa" uniqKey="Holguin A" first="Africa" last="Holguín">Africa Holguín</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Doruana, Manuela" sort="Doruana, Manuela" uniqKey="Doruana M" first="Manuela" last="Doruana">Manuela Doruana</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Antunes, Rute" sort="Antunes, Rute" uniqKey="Antunes R" first="Rute" last="Antunes">Rute Antunes</name>
<affiliation><mods:affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mansinho, Kamal" sort="Mansinho, Kamal" uniqKey="Mansinho K" first="Kamal" last="Mansinho">Kamal Mansinho</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Switzer, William M" sort="Switzer, William M" uniqKey="Switzer W" first="William M." last="Switzer">William M. Switzer</name>
<affiliation><mods:affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Araujo, Carlos" sort="Araujo, Carlos" uniqKey="Araujo C" first="Carlos" last="Araujo">Carlos Araujo</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Shanmugam, Vedapuri" sort="Shanmugam, Vedapuri" uniqKey="Shanmugam V" first="Vedapuri" last="Shanmugam">Vedapuri Shanmugam</name>
<affiliation><mods:affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lourenco, Helena" sort="Lourenco, Helena" uniqKey="Lourenco H" first="Helena" last="Lourenço">Helena Lourenço</name>
<affiliation><mods:affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Gonzalez Ahoz, Juan" sort="Gonzalez Ahoz, Juan" uniqKey="Gonzalez Ahoz J" first="Juan" last="González-Lahoz">Juan González-Lahoz</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Antunes, Francisco" sort="Antunes, Francisco" uniqKey="Antunes F" first="Francisco" last="Antunes">Francisco Antunes</name>
<affiliation><mods:affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Journal of Medical Virology</title>
<title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title>
<idno type="ISSN">0146-6615</idno>
<idno type="eISSN">1096-9071</idno>
<imprint><biblScope unit="vol">61</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="111">111</biblScope>
<biblScope unit="page" to="116">116</biblScope>
<biblScope unit="page-count">6</biblScope>
<publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-05">2000-05</date>
</imprint>
<idno type="ISSN">0146-6615</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>African origin</term>
<term>Aids cases</term>
<term>Amplification</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Antiretroviral treatment</term>
<term>Assay</term>
<term>Classification system</term>
<term>Clin microbiol</term>
<term>Clinical manifestations</term>
<term>Clinical status</term>
<term>Comissao nacional</term>
<term>Comunidad autonoma</term>
<term>Copy numbers</term>
<term>Disease progression</term>
<term>Epidemiological purposes</term>
<term>Equatorial guinea</term>
<term>Grant sponsor</term>
<term>Heterosexual contact</term>
<term>Htsex</term>
<term>Human immunodeficiency virus type</term>
<term>Immunodeficiency</term>
<term>Immunological status</term>
<term>Infection</term>
<term>Infectious diseases</term>
<term>Instances values</term>
<term>Internal control</term>
<term>Ivory coast</term>
<term>Lisbon</term>
<term>Luta contra</term>
<term>Main subtypes</term>
<term>Main virological features</term>
<term>Natural history</term>
<term>Pbmcs</term>
<term>Peripheral blood</term>
<term>Phylogenetic analysis</term>
<term>Plasma viraemia</term>
<term>Portugal</term>
<term>Quantitation</term>
<term>Retroviruses heredia</term>
<term>Rflp method</term>
<term>Salud carlos</term>
<term>Sequence analysis</term>
<term>Soriano</term>
<term>Study population</term>
<term>Subtype</term>
<term>Subtypes</term>
<term>Symptomatic disease</term>
<term>Transcriptase assay</term>
<term>Viraemia</term>
<term>Viral</term>
<term>Viral load</term>
<term>Virus</term>
<term>Virus isolation</term>
<term>Virus recovery</term>
<term>West africa</term>
<term>Wild type</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>African origin</term>
<term>Aids cases</term>
<term>Amplification</term>
<term>Antiretroviral</term>
<term>Antiretroviral therapy</term>
<term>Antiretroviral treatment</term>
<term>Assay</term>
<term>Classification system</term>
<term>Clin microbiol</term>
<term>Clinical manifestations</term>
<term>Clinical status</term>
<term>Comissao nacional</term>
<term>Comunidad autonoma</term>
<term>Copy numbers</term>
<term>Disease progression</term>
<term>Epidemiological purposes</term>
<term>Equatorial guinea</term>
<term>Grant sponsor</term>
<term>Heterosexual contact</term>
<term>Htsex</term>
<term>Human immunodeficiency virus type</term>
<term>Immunodeficiency</term>
<term>Immunological status</term>
<term>Infection</term>
<term>Infectious diseases</term>
<term>Instances values</term>
<term>Internal control</term>
<term>Ivory coast</term>
<term>Lisbon</term>
<term>Luta contra</term>
<term>Main subtypes</term>
<term>Main virological features</term>
<term>Natural history</term>
<term>Pbmcs</term>
<term>Peripheral blood</term>
<term>Phylogenetic analysis</term>
<term>Plasma viraemia</term>
<term>Portugal</term>
<term>Quantitation</term>
<term>Retroviruses heredia</term>
<term>Rflp method</term>
<term>Salud carlos</term>
<term>Sequence analysis</term>
<term>Soriano</term>
<term>Study population</term>
<term>Subtype</term>
<term>Subtypes</term>
<term>Symptomatic disease</term>
<term>Transcriptase assay</term>
<term>Viraemia</term>
<term>Viral</term>
<term>Viral load</term>
<term>Virus</term>
<term>Virus isolation</term>
<term>Virus recovery</term>
<term>West africa</term>
<term>Wild type</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as more pathogenic than the rest. The relationship between the clinical status and levels of both cellular and plasma HIV‐2 viraemia is not well known, nor their modifications under antiretroviral therapy. Thirty‐two consecutive HIV‐2 infected persons (17 men, 15 women) attending two different hospitals in Lisbon in 1997 were enrolled prospectively in the study. All but 4 individuals most likely acquired the infection through heterosexual contact. More than half of the study population was of African origin, mainly from Guinea‐Bissau. Eleven (34.4%) patients had developed clinical manifestations included within the B or C groups of the CDC classification system for HIV infection, with the rest being asymptomatic. Half of the population was undergoing antiretroviral treatment at the time of the study. HIV‐2 subtypes were investigated using a new Nef‐based restriction fragment length polymorphism (RFLP) method that allows differentiation of the main two variants, A and B. Plasma viral load was quantified using a new quantitative competitive reverse transcriptase polymerase chain reaction (QcRT‐PCR) procedure as well as the Amp‐RT assay. Virus isolation was attempted from peripheral blood mononuclear cells. All but one person carried HIV‐2 subtype A. Plasma viraemia examined by QcRT‐PCR was measurable in 15 (50%) of 30 subjects, yielding in all instances values below 20,000 HIV‐2 RNA copies per ml. Plasma RT activity could be detected in only 10 (33%) of 30 subjects, a rate much lower than that seen in HIV‐1 infection. Virus was isolated from 16 (53.3%) of 30 patients. A significant correlation was found between CD4+ counts, clinical status, rate of virus isolation, and plasma viral load by both QcRT‐PCR and Amp‐RT. In conclusion, HIV‐2 subtype A is the predominant variant circulating in Portugal among both natives and immigrants. A lower cellular and plasma viral load with respect to HIV‐1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low. J. Med. Virol. 61:111–116, 2000. © 2000 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>htsex</json:string>
<json:string>immunodeficiency</json:string>
<json:string>viraemia</json:string>
<json:string>soriano</json:string>
<json:string>human immunodeficiency virus type</json:string>
<json:string>antiretroviral</json:string>
<json:string>plasma viraemia</json:string>
<json:string>subtypes</json:string>
<json:string>virus isolation</json:string>
<json:string>quantitation</json:string>
<json:string>pbmcs</json:string>
<json:string>viral</json:string>
<json:string>antiretroviral therapy</json:string>
<json:string>assay</json:string>
<json:string>clinical status</json:string>
<json:string>study population</json:string>
<json:string>infectious diseases</json:string>
<json:string>grant sponsor</json:string>
<json:string>subtype</json:string>
<json:string>portugal</json:string>
<json:string>lisbon</json:string>
<json:string>sequence analysis</json:string>
<json:string>west africa</json:string>
<json:string>comissao nacional</json:string>
<json:string>luta contra</json:string>
<json:string>clinical manifestations</json:string>
<json:string>peripheral blood</json:string>
<json:string>african origin</json:string>
<json:string>classification system</json:string>
<json:string>salud carlos</json:string>
<json:string>internal control</json:string>
<json:string>ivory coast</json:string>
<json:string>immunological status</json:string>
<json:string>virus recovery</json:string>
<json:string>aids cases</json:string>
<json:string>epidemiological purposes</json:string>
<json:string>main virological features</json:string>
<json:string>antiretroviral treatment</json:string>
<json:string>clin microbiol</json:string>
<json:string>disease progression</json:string>
<json:string>rflp method</json:string>
<json:string>comunidad autonoma</json:string>
<json:string>transcriptase assay</json:string>
<json:string>retroviruses heredia</json:string>
<json:string>wild type</json:string>
<json:string>copy numbers</json:string>
<json:string>heterosexual contact</json:string>
<json:string>instances values</json:string>
<json:string>symptomatic disease</json:string>
<json:string>equatorial guinea</json:string>
<json:string>main subtypes</json:string>
<json:string>viral load</json:string>
<json:string>natural history</json:string>
<json:string>phylogenetic analysis</json:string>
<json:string>amplification</json:string>
<json:string>infection</json:string>
<json:string>virus</json:string>
</teeft>
</keywords>
<author><json:item><name>Vincent Soriano</name>
<affiliations><json:string>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</json:string>
<json:string>C/Rafael Calvo 7, 2° A, 28010 Madrid, Spain===</json:string>
</affiliations>
</json:item>
<json:item><name>Perpétua Gomes</name>
<affiliations><json:string>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</json:string>
</affiliations>
</json:item>
<json:item><name>Walid Heneine</name>
<affiliations><json:string>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</json:string>
</affiliations>
</json:item>
<json:item><name>Africa Holguín</name>
<affiliations><json:string>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</json:string>
</affiliations>
</json:item>
<json:item><name>Manuela Doruana</name>
<affiliations><json:string>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</json:string>
</affiliations>
</json:item>
<json:item><name>Rute Antunes</name>
<affiliations><json:string>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</json:string>
</affiliations>
</json:item>
<json:item><name>Kamal Mansinho</name>
<affiliations><json:string>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</json:string>
</affiliations>
</json:item>
<json:item><name>William M. Switzer</name>
<affiliations><json:string>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</json:string>
</affiliations>
</json:item>
<json:item><name>Carlos Araujo</name>
<affiliations><json:string>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</json:string>
</affiliations>
</json:item>
<json:item><name>Vedapuri Shanmugam</name>
<affiliations><json:string>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</json:string>
</affiliations>
</json:item>
<json:item><name>Helena Lourenço</name>
<affiliations><json:string>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</json:string>
</affiliations>
</json:item>
<json:item><name>Juan González‐Lahoz</name>
<affiliations><json:string>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</json:string>
</affiliations>
</json:item>
<json:item><name>Francisco Antunes</name>
<affiliations><json:string>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>HIV‐2</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>subtypes</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>viraemia</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>epidemiology</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Portugal</value>
</json:item>
</subject>
<articleId><json:string>JMV18</json:string>
</articleId>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>article</json:string>
</originalGenre>
<abstract>The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as more pathogenic than the rest. The relationship between the clinical status and levels of both cellular and plasma HIV‐2 viraemia is not well known, nor their modifications under antiretroviral therapy. Thirty‐two consecutive HIV‐2 infected persons (17 men, 15 women) attending two different hospitals in Lisbon in 1997 were enrolled prospectively in the study. All but 4 individuals most likely acquired the infection through heterosexual contact. More than half of the study population was of African origin, mainly from Guinea‐Bissau. Eleven (34.4%) patients had developed clinical manifestations included within the B or C groups of the CDC classification system for HIV infection, with the rest being asymptomatic. Half of the population was undergoing antiretroviral treatment at the time of the study. HIV‐2 subtypes were investigated using a new Nef‐based restriction fragment length polymorphism (RFLP) method that allows differentiation of the main two variants, A and B. Plasma viral load was quantified using a new quantitative competitive reverse transcriptase polymerase chain reaction (QcRT‐PCR) procedure as well as the Amp‐RT assay. Virus isolation was attempted from peripheral blood mononuclear cells. All but one person carried HIV‐2 subtype A. Plasma viraemia examined by QcRT‐PCR was measurable in 15 (50%) of 30 subjects, yielding in all instances values below 20,000 HIV‐2 RNA copies per ml. Plasma RT activity could be detected in only 10 (33%) of 30 subjects, a rate much lower than that seen in HIV‐1 infection. Virus was isolated from 16 (53.3%) of 30 patients. A significant correlation was found between CD4+ counts, clinical status, rate of virus isolation, and plasma viral load by both QcRT‐PCR and Amp‐RT. In conclusion, HIV‐2 subtype A is the predominant variant circulating in Portugal among both natives and immigrants. A lower cellular and plasma viral load with respect to HIV‐1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low. J. Med. Virol. 61:111–116, 2000. © 2000 Wiley‐Liss, Inc.</abstract>
<qualityIndicators><score>7.077</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>612 x 792 pts (letter)</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>2251</abstractCharCount>
<pdfWordCount>4077</pdfWordCount>
<pdfCharCount>26169</pdfCharCount>
<pdfPageCount>6</pdfPageCount>
<abstractWordCount>347</abstractWordCount>
</qualityIndicators>
<title>Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
<genre><json:string>article</json:string>
</genre>
<host><title>Journal of Medical Virology</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1002/(ISSN)1096-9071</json:string>
</doi>
<issn><json:string>0146-6615</json:string>
</issn>
<eissn><json:string>1096-9071</json:string>
</eissn>
<publisherId><json:string>JMV</json:string>
</publisherId>
<volume>61</volume>
<issue>1</issue>
<pages><first>111</first>
<last>116</last>
<total>6</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<categories><wos><json:string>science</json:string>
<json:string>virology</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>biomedical research</json:string>
<json:string>virology</json:string>
</scienceMetrix>
<inist><json:string>sciences appliquees, technologies et medecines</json:string>
<json:string>sciences biologiques et medicales</json:string>
<json:string>sciences medicales</json:string>
<json:string>endocrinopathies</json:string>
</inist>
</categories>
<publicationDate>2000</publicationDate>
<copyrightDate>2000</copyrightDate>
<doi><json:string>10.1002/(SICI)1096-9071(200005)61:1>111::AID-JMV18>3.0.CO;2-W</json:string>
</doi>
<id>F14A622501FF9A53D5567AD920B384E3635A1D01</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/F14A622501FF9A53D5567AD920B384E3635A1D01/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/F14A622501FF9A53D5567AD920B384E3635A1D01/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/F14A622501FF9A53D5567AD920B384E3635A1D01/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<availability><licence>Copyright © 2000 Wiley‐Liss, Inc.</licence>
</availability>
<date type="published" when="2000-05"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
<title level="a" type="short" xml:lang="en">Human Immunodeficiency Virus Type 2 (HIV‐2) in Portugal</title>
<author xml:id="author-0000" role="corresp"><persName><forename type="first">Vincent</forename>
<surname>Soriano</surname>
</persName>
<email>vsoriano@dragonet.es</email>
<affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain<address><country key="ES"></country>
</address>
</affiliation>
<affiliation>C/Rafael Calvo 7, 2° A, 28010 Madrid, Spain===</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">Perpétua</forename>
<surname>Gomes</surname>
</persName>
<affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal<address><country key="PT"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">Walid</forename>
<surname>Heneine</surname>
</persName>
<affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">Africa</forename>
<surname>Holguín</surname>
</persName>
<affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain<address><country key="ES"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">Manuela</forename>
<surname>Doruana</surname>
</persName>
<affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal<address><country key="PT"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">Rute</forename>
<surname>Antunes</surname>
</persName>
<affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal<address><country key="PT"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0006"><persName><forename type="first">Kamal</forename>
<surname>Mansinho</surname>
</persName>
<affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal<address><country key="PT"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0007"><persName><forename type="first">William M.</forename>
<surname>Switzer</surname>
</persName>
<affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0008"><persName><forename type="first">Carlos</forename>
<surname>Araujo</surname>
</persName>
<affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal<address><country key="PT"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0009"><persName><forename type="first">Vedapuri</forename>
<surname>Shanmugam</surname>
</persName>
<affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia<address><country key="US"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0010"><persName><forename type="first">Helena</forename>
<surname>Lourenço</surname>
</persName>
<affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal<address><country key="PT"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0011"><persName><forename type="first">Juan</forename>
<surname>González‐Lahoz</surname>
</persName>
<affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain<address><country key="ES"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0012"><persName><forename type="first">Francisco</forename>
<surname>Antunes</surname>
</persName>
<affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal<address><country key="PT"></country>
</address>
</affiliation>
</author>
<idno type="istex">F14A622501FF9A53D5567AD920B384E3635A1D01</idno>
<idno type="ark">ark:/67375/WNG-J1RGP8RS-T</idno>
<idno type="DOI">10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W</idno>
<idno type="unit">JMV18</idno>
<idno type="toTypesetVersion">file:JMV.JMV18.pdf</idno>
</analytic>
<monogr><title level="j" type="main">Journal of Medical Virology</title>
<title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title>
<idno type="pISSN">0146-6615</idno>
<idno type="eISSN">1096-9071</idno>
<idno type="book-DOI">10.1002/(ISSN)1096-9071</idno>
<idno type="book-part-DOI">10.1002/(SICI)1096-9071(200005)61:1<>1.0.CO;2-Q</idno>
<idno type="product">JMV</idno>
<imprint><biblScope unit="vol">61</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="111">111</biblScope>
<biblScope unit="page" to="116">116</biblScope>
<biblScope unit="page-count">6</biblScope>
<publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-05"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head>
<p>The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as more pathogenic than the rest. The relationship between the clinical status and levels of both cellular and plasma HIV‐2 viraemia is not well known, nor their modifications under antiretroviral therapy. Thirty‐two consecutive HIV‐2 infected persons (17 men, 15 women) attending two different hospitals in Lisbon in 1997 were enrolled prospectively in the study. All but 4 individuals most likely acquired the infection through heterosexual contact. More than half of the study population was of African origin, mainly from Guinea‐Bissau. Eleven (34.4%) patients had developed clinical manifestations included within the B or C groups of the CDC classification system for HIV infection, with the rest being asymptomatic. Half of the population was undergoing antiretroviral treatment at the time of the study. HIV‐2 subtypes were investigated using a new <hi rend="italic">Nef</hi>
‐based restriction fragment length polymorphism (RFLP) method that allows differentiation of the main two variants, A and B. Plasma viral load was quantified using a new quantitative competitive reverse transcriptase polymerase chain reaction (QcRT‐PCR) procedure as well as the Amp‐RT assay. Virus isolation was attempted from peripheral blood mononuclear cells. All but one person carried HIV‐2 subtype A. Plasma viraemia examined by QcRT‐PCR was measurable in 15 (50%) of 30 subjects, yielding in all instances values below 20,000 HIV‐2 RNA copies per ml. Plasma RT activity could be detected in only 10 (33%) of 30 subjects, a rate much lower than that seen in HIV‐1 infection. Virus was isolated from 16 (53.3%) of 30 patients. A significant correlation was found between CD4+ counts, clinical status, rate of virus isolation, and plasma viral load by both QcRT‐PCR and Amp‐RT. In conclusion, HIV‐2 subtype A is the predominant variant circulating in Portugal among both natives and immigrants. A lower cellular and plasma viral load with respect to HIV‐1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low. J. Med. Virol. 61:111–116, 2000. © 2000 Wiley‐Liss, Inc.</p>
</abstract>
<textClass><keywords xml:lang="en"><term xml:id="kwd1">HIV‐2</term>
<term xml:id="kwd2">subtypes</term>
<term xml:id="kwd3">viraemia</term>
<term xml:id="kwd4">epidemiology</term>
<term xml:id="kwd5">Portugal</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/F14A622501FF9A53D5567AD920B384E3635A1D01/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName>
<publisherLoc>New York</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1096-9071</doi>
<issn type="print">0146-6615</issn>
<issn type="electronic">1096-9071</issn>
<idGroup><id type="product" value="JMV"></id>
</idGroup>
<titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF MEDICAL VIROLOGY">Journal of Medical Virology</title>
<title type="short">J. Med. Virol.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/(SICI)1096-9071(200005)61:1<>1.0.CO;2-Q</doi>
<numberingGroup><numbering type="journalVolume" number="61">61</numbering>
<numbering type="journalIssue">1</numbering>
</numberingGroup>
<coverDate startDate="2000-05">May 2000</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="article" position="18" status="forIssue"><doi origin="wiley" registered="yes">10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W</doi>
<idGroup><id type="unit" value="JMV18"></id>
</idGroup>
<countGroup><count type="pageTotal" number="6"></count>
</countGroup>
<copyright ownership="publisher">Copyright © 2000 Wiley‐Liss, Inc.</copyright>
<eventGroup><event type="manuscriptAccepted" date="1999-10-19"></event>
<event type="firstOnline" date="2000-03-31"></event>
<event type="publishedOnlineFinalForm" date="2000-03-31"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-15"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-20"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">111</numbering>
<numbering type="pageLast">116</numbering>
</numberingGroup>
<correspondenceTo>C/Rafael Calvo 7, 2° A, 28010 Madrid, Spain===</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:JMV.JMV18.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><countGroup><count type="figureTotal" number="0"></count>
<count type="tableTotal" number="2"></count>
<count type="referenceTotal" number="42"></count>
<count type="wordTotal" number="3986"></count>
</countGroup>
<titleGroup><title type="main" xml:lang="en">Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
<title type="short" xml:lang="en">Human Immunodeficiency Virus Type 2 (HIV‐2) in Portugal</title>
</titleGroup>
<creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Vincent</givenNames>
<familyName>Soriano</familyName>
</personName>
<contactDetails><email>vsoriano@dragonet.es</email>
</contactDetails>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Perpétua</givenNames>
<familyName>Gomes</familyName>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Walid</givenNames>
<familyName>Heneine</familyName>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Africa</givenNames>
<familyName>Holguín</familyName>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Manuela</givenNames>
<familyName>Doruana</familyName>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Rute</givenNames>
<familyName>Antunes</familyName>
</personName>
</creator>
<creator xml:id="au7" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Kamal</givenNames>
<familyName>Mansinho</familyName>
</personName>
</creator>
<creator xml:id="au8" creatorRole="author" affiliationRef="#af3"><personName><givenNames>William M.</givenNames>
<familyName>Switzer</familyName>
</personName>
</creator>
<creator xml:id="au9" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Carlos</givenNames>
<familyName>Araujo</familyName>
</personName>
</creator>
<creator xml:id="au10" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Vedapuri</givenNames>
<familyName>Shanmugam</familyName>
</personName>
</creator>
<creator xml:id="au11" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Helena</givenNames>
<familyName>Lourenço</familyName>
</personName>
</creator>
<creator xml:id="au12" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Juan</givenNames>
<familyName>González‐Lahoz</familyName>
</personName>
</creator>
<creator xml:id="au13" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Francisco</givenNames>
<familyName>Antunes</familyName>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="PT" type="organization"><unparsedAffiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af4" countryCode="PT" type="organization"><unparsedAffiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af5" countryCode="PT" type="organization"><unparsedAffiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">HIV‐2</keyword>
<keyword xml:id="kwd2">subtypes</keyword>
<keyword xml:id="kwd3">viraemia</keyword>
<keyword xml:id="kwd4">epidemiology</keyword>
<keyword xml:id="kwd5">Portugal</keyword>
</keywordGroup>
<fundingInfo><fundingAgency>Instituto de Salud Carlos III</fundingAgency>
</fundingInfo>
<fundingInfo><fundingAgency>Comunidad Autónoma de Madrid</fundingAgency>
</fundingInfo>
<fundingInfo><fundingAgency>Programa Praxis XXI/2/2</fundingAgency>
<fundingNumber>BD/2224/92‐ID, 1/SAU/16/94</fundingNumber>
</fundingInfo>
<fundingInfo><fundingAgency>Junta Nacional de Investigação Científica e Tecnológica and Comissão Nacional de Luta Contra a SIDA</fundingAgency>
<fundingNumber>1/SAU/16/94</fundingNumber>
</fundingInfo>
<abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title>
<p>The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as more pathogenic than the rest. The relationship between the clinical status and levels of both cellular and plasma HIV‐2 viraemia is not well known, nor their modifications under antiretroviral therapy. Thirty‐two consecutive HIV‐2 infected persons (17 men, 15 women) attending two different hospitals in Lisbon in 1997 were enrolled prospectively in the study. All but 4 individuals most likely acquired the infection through heterosexual contact. More than half of the study population was of African origin, mainly from Guinea‐Bissau. Eleven (34.4%) patients had developed clinical manifestations included within the B or C groups of the CDC classification system for HIV infection, with the rest being asymptomatic. Half of the population was undergoing antiretroviral treatment at the time of the study. HIV‐2 subtypes were investigated using a new <i>Nef</i>
‐based restriction fragment length polymorphism (RFLP) method that allows differentiation of the main two variants, A and B. Plasma viral load was quantified using a new quantitative competitive reverse transcriptase polymerase chain reaction (QcRT‐PCR) procedure as well as the Amp‐RT assay. Virus isolation was attempted from peripheral blood mononuclear cells. All but one person carried HIV‐2 subtype A. Plasma viraemia examined by QcRT‐PCR was measurable in 15 (50%) of 30 subjects, yielding in all instances values below 20,000 HIV‐2 RNA copies per ml. Plasma RT activity could be detected in only 10 (33%) of 30 subjects, a rate much lower than that seen in HIV‐1 infection. Virus was isolated from 16 (53.3%) of 30 patients. A significant correlation was found between CD4+ counts, clinical status, rate of virus isolation, and plasma viral load by both QcRT‐PCR and Amp‐RT. In conclusion, HIV‐2 subtype A is the predominant variant circulating in Portugal among both natives and immigrants. A lower cellular and plasma viral load with respect to HIV‐1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low. J. Med. Virol. 61:111–116, 2000. © 2000 Wiley‐Liss, Inc.</p>
</abstract>
</abstractGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en"><title>Human Immunodeficiency Virus Type 2 (HIV‐2) in Portugal</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load</title>
</titleInfo>
<name type="personal"><namePart type="given">Vincent</namePart>
<namePart type="family">Soriano</namePart>
<affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</affiliation>
<affiliation>E-mail: vsoriano@dragonet.es</affiliation>
<affiliation>Correspondence address: C/Rafael Calvo 7, 2° A, 28010 Madrid, Spain===</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Perpétua</namePart>
<namePart type="family">Gomes</namePart>
<affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Walid</namePart>
<namePart type="family">Heneine</namePart>
<affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Africa</namePart>
<namePart type="family">Holguín</namePart>
<affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Manuela</namePart>
<namePart type="family">Doruana</namePart>
<affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Rute</namePart>
<namePart type="family">Antunes</namePart>
<affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Kamal</namePart>
<namePart type="family">Mansinho</namePart>
<affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">William M.</namePart>
<namePart type="family">Switzer</namePart>
<affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Carlos</namePart>
<namePart type="family">Araujo</namePart>
<affiliation>Service of Infectious Diseases, Hospital Egas‐Moniz, Lisbon, Portugal</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Vedapuri</namePart>
<namePart type="family">Shanmugam</namePart>
<affiliation>HIV and Retrovirology Branch, National Center for Infectious Diseases, CDC, Atlanta, Georgia</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Helena</namePart>
<namePart type="family">Lourenço</namePart>
<affiliation>Laboratory of Virology, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Juan</namePart>
<namePart type="family">González‐Lahoz</namePart>
<affiliation>Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Francisco</namePart>
<namePart type="family">Antunes</namePart>
<affiliation>Service of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre>
<originInfo><publisher>John Wiley & Sons, Inc.</publisher>
<place><placeTerm type="text">New York</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2000-05</dateIssued>
<dateValid encoding="w3cdtf">1999-10-19</dateValid>
<copyrightDate encoding="w3cdtf">2000</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><extent unit="figures">0</extent>
<extent unit="tables">2</extent>
<extent unit="references">42</extent>
<extent unit="words">3986</extent>
</physicalDescription>
<abstract lang="en">The human immunodeficiency virus type 2 (HIV‐2) is responsible for 4.5% of AIDS cases in Portugal. Six HIV‐2 subtypes have been described so far, subtype A being proposed as more pathogenic than the rest. The relationship between the clinical status and levels of both cellular and plasma HIV‐2 viraemia is not well known, nor their modifications under antiretroviral therapy. Thirty‐two consecutive HIV‐2 infected persons (17 men, 15 women) attending two different hospitals in Lisbon in 1997 were enrolled prospectively in the study. All but 4 individuals most likely acquired the infection through heterosexual contact. More than half of the study population was of African origin, mainly from Guinea‐Bissau. Eleven (34.4%) patients had developed clinical manifestations included within the B or C groups of the CDC classification system for HIV infection, with the rest being asymptomatic. Half of the population was undergoing antiretroviral treatment at the time of the study. HIV‐2 subtypes were investigated using a new Nef‐based restriction fragment length polymorphism (RFLP) method that allows differentiation of the main two variants, A and B. Plasma viral load was quantified using a new quantitative competitive reverse transcriptase polymerase chain reaction (QcRT‐PCR) procedure as well as the Amp‐RT assay. Virus isolation was attempted from peripheral blood mononuclear cells. All but one person carried HIV‐2 subtype A. Plasma viraemia examined by QcRT‐PCR was measurable in 15 (50%) of 30 subjects, yielding in all instances values below 20,000 HIV‐2 RNA copies per ml. Plasma RT activity could be detected in only 10 (33%) of 30 subjects, a rate much lower than that seen in HIV‐1 infection. Virus was isolated from 16 (53.3%) of 30 patients. A significant correlation was found between CD4+ counts, clinical status, rate of virus isolation, and plasma viral load by both QcRT‐PCR and Amp‐RT. In conclusion, HIV‐2 subtype A is the predominant variant circulating in Portugal among both natives and immigrants. A lower cellular and plasma viral load with respect to HIV‐1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low. J. Med. Virol. 61:111–116, 2000. © 2000 Wiley‐Liss, Inc.</abstract>
<note type="funding">Instituto de Salud Carlos III</note>
<note type="funding">Comunidad Autónoma de Madrid</note>
<note type="funding">Programa Praxis XXI/2/2 - No. BD/2224/92‐ID, 1/SAU/16/94; </note>
<note type="funding">Junta Nacional de Investigação Científica e Tecnológica and Comissão Nacional de Luta Contra a SIDA - No. 1/SAU/16/94; </note>
<subject lang="en"><genre>keywords</genre>
<topic>HIV‐2</topic>
<topic>subtypes</topic>
<topic>viraemia</topic>
<topic>epidemiology</topic>
<topic>Portugal</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Journal of Medical Virology</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J. Med. Virol.</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">0146-6615</identifier>
<identifier type="eISSN">1096-9071</identifier>
<identifier type="DOI">10.1002/(ISSN)1096-9071</identifier>
<identifier type="PublisherID">JMV</identifier>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>61</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>111</start>
<end>116</end>
<total>6</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">F14A622501FF9A53D5567AD920B384E3635A1D01</identifier>
<identifier type="ark">ark:/67375/WNG-J1RGP8RS-T</identifier>
<identifier type="DOI">10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W</identifier>
<identifier type="ArticleID">JMV18</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Wiley‐Liss, Inc.</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>John Wiley & Sons, Inc.</recordOrigin>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/document/F14A622501FF9A53D5567AD920B384E3635A1D01/metadata/json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E57 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 004E57 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:F14A622501FF9A53D5567AD920B384E3635A1D01
   |texte=   Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load
}}

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024

	Le SIDA en Afrique subsaharienne (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA en Afrique subsaharienne (serveur d'exploration)

Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load

Human immunodeficiency virus type 2 (HIV‐2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri